कोशिश गोल्ड - मुक्त

India, critical player in global health & wellness arena

Chronicle Pharmabiz

|

November 27, 2025

The Indian nutraceutical industry is pursuing innovation, coupled with stronger international cooperation and standardized regulations.

- Our Bureau, Bengaluru

India, critical player in global health & wellness arena

With this India is not just participating in the global nutraceutical game anymore. The industry here is actually in a position to note merely engaged in the marketing nutraceutical products but cementing a spot as an absolutely crucial player in the entire global health and wellness arena with real impact, opine experts.

India has a capability to contribute to the global regulatory conversation. By blending our traditional health systems, like Ayurveda, along with scientific capabilities, we can help craft entirely new frameworks for safe and effective botanical and functional food ingredients worldwide. Here we are ready to lead, said Gaurav Soni, co-founder & managing director, Botanic Healthcare.

The need of the hour is expedited approvals for ingredients that are already recognized worldwide. There is a need for official acknowledgment of international monographs and reference materials. There needs to be incentives for companies to get global certifications like US FDA-GMP, EU-GMP, and NSF. Another is a central digital hub that gives us real-time regulatory intelligence across different countries with a big push for collaborative research on safety and effectiveness, pointed out Soni.

Noting that it is heartwarming to see that Indian businesses are not just sitting back, Soni said that companies are instead actively implementing international best practices, investing into clinical research, seeking third-party certifications, adopting open sourcing, and focusing on sustainable manufacturing.

Nutra industry on an accelerated growth path

With shifting consumer mindsets, increasing disposable incomes, and robust regulatory frameworks, India's nutraceutical market is poised to become a global powerhouse in preventive healthcare and wellness.

Chronicle Pharmabiz से और कहानियाँ

Chronicle Pharmabiz

US FDA fortifies alliance with Telangana DCA

A high-level delegation from the US FDA concluded a significant meeting with the DCA in Telangana, two days ago, at the DCA office in Hyderabad.

time to read

2 mins

December 11, 2025

Chronicle Pharmabiz

India exploring possibilities to expand WHO standards for Indian medicines

INDIA is looking at possibilities to expand the World Health Organisation (WHO) global benchmarking standards for medicines, in order to unify and strengthen the drug regulatory mechanism for safety, quality and efficacy of medicines sold in the country.

time to read

1 min

December 11, 2025

Chronicle Pharmabiz

Eli Lilly gets US FDA approval for Jaypirca

Eli Lilly and Company announced that the US Food and Drug Administration (FDA) has granted approval to Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adults with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent Bruton tyrosine kinase (BTK) inhibitor.

time to read

1 mins

December 11, 2025

Chronicle Pharmabiz

Haryana DCA focuses on quality overhaul

THE Haryana drug control administration (DCA) is undertaking a major organizational overhaul focused on quality system upgrades and regulatory capacity building, particularly in response to the revised Schedule M norms.

time to read

2 mins

December 11, 2025

Chronicle Pharmabiz

DoC seeks inputs on trade issues faced with Japan

THE Department of Commerce (DoC), under the Union Commerce Ministry, has sought inputs from the industry on specific issues being faced in pharma trade with Japan.

time to read

1 min

December 11, 2025

Chronicle Pharmabiz

AIOCD asks traders to strictly comply with ban on 35 FDCs

THE All India Organisation of Chemists and Druggists (AIOCD) has issued an urgent internal circular to all its state and Union territory trade bodies, demanding immediate and strict compliance with the ban on 35 fixed dose combinations (FDCs).

time to read

3 mins

December 11, 2025

Chronicle Pharmabiz

US FDA approves Bristol Myers Squibb's Breyanzi

Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) has granted approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy.

time to read

2 mins

December 11, 2025

Chronicle Pharmabiz

CN Water presents AQU@Sense MB

CN Water is now combining core water-system expertise with digital assurance has launched AQU@Sense which delivers microbial test results in under 30 minutes, replacing traditional 5 to 7 days culture based methods.

time to read

1 min

December 11, 2025

Chronicle Pharmabiz

Pharma logistics sees policy push as key catalyst for growth

INDIAN pharma's logistics sector is getting major boost from emerging policy support.

time to read

2 mins

December 11, 2025

Chronicle Pharmabiz

Lack of financial aid, expertise mar MSME prospects to meet revised Sch M deadline

INDUSTRY experts have raised alarm that lack of financial assistance and guidance on technical expertise have marred pharma MSMEs’ prospects to comply with revised Schedule M guidelines of December 31, 2025.

time to read

2 mins

December 11, 2025

Listen

Translate

Share

-
+

Change font size